Want to join the conversation?
$ESRX, which competes with $UNH and $ANTM, said that the the company delivers on controlling costs and achieving better patient outcomes. In situations where drug prices rise and complex regulations increase, the company finds out innovative ways to strengthen the pharmacy benefit, while improving care.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.